MedTrace Logo

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

NCT04435652 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 492

Last updated 2020-06-17

No results posted yet for this study

Summary

This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who had tumor progression after first-line treatment with platinum and fluoropyrimidine doublet therapy. The study will be conducted in 2 parts.

Conditions

  • Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

QL1604

3mg/kg, D1,8,15,Q4w, IV infusion

DRUG

Nab-paclitaxel

100mg/m2, D1,8,15,Q4w, IV infusion

DRUG

Paclitaxel

80mg/m2, D1,8,15,Q4w, IV infusion

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2022-04-30
Completion
2022-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04435652 on ClinicalTrials.gov